Lyudmila Bazhenova
Dr. Bazhenova is a Clinical Professor of Medicine at UC San Diego Moores Cancer Center, Lung Cancer Unit Leader and a Director of the Hematology Oncology training program. Dr. Bazhenova’s clinical practice and research concentrate on lung cancer. Dr. Bazhenova has vast experience in clinical trial management, design and implementation. She serves Chair of UC San Diego Protocol Review and Monitoring committee. Dr. Bazhenova is a member of Alliance Respiratory Committee. She is a recipient of NCI Clinical Trial Leadership Award, San Diego Best Doctors awards and Women Who Mean Business Award. Her main research interest is drug development.
Dr. Bazhenova completed her M.D. at Nizhny Novgorod State Medical Academy in Nizhny Novgorod, Russia. She graduated from Internal medicine residency at University of California Los Angeles/ West Los Angeles VA medical center and then completed a fellowship in Hematology-Oncology at Scripps-Green Hospital in La Jolla in 2005 and has been in practice at NCI designated UC San Diego Moores Cancer Center since 2005.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:NeuvogenTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:IntervennTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Elevation OncologyTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ORICTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:NovocureTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:regeneronTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MiratiTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Turning pointTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:DaichiTopic:lung cancerDate added:08/12/2022Date updated:08/12/2022